ELTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.5M
-19.0%
10.4M
-1.6%
10.6M
+19.9%
8.8M
+9.9%
8.0M
R&D
4.9M
-28.2%
6.8M
+0.8%
6.8M
+33.0%
5.1M
+0.8%
5.0M
SG&A
3.6M
-1.5%
3.6M
-5.9%
3.8M
+2.2%
3.8M
+25.1%
3.0M
Operating Income
-8452000
+19.0%
-10429000
+1.6%
-10602000
-19.9%
-8842000
-9.9%
-8045000
EBITDA
-8421000
+19.0%
-10393000
+1.5%
-10556000
-20.1%
-8793000
-10.0%
-7996000
Net Income
-7979000
+2.9%
-8217000
+30.5%
-11823000
-53.2%
-7718000
+23.5%
-10083000
EPS (Basic)
$-0.30
+30.2%
$-0.43
+33.8%
$-0.65
-30.0%
$-0.50
+16.7%
$-0.60
EPS (Diluted)
$-0.30
+30.2%
$-0.43
+33.8%
$-0.65
-30.0%
$-0.50
+16.7%
$-0.60
Shares (Diluted)
26.3M
+36.6%
19.2M
+5.7%
18.2M
+17.1%
15.5M
-6.9%
16.7M
Elicio Therapeutics (ELTX) — Financials